Laryngeal mask airway surfactant administration: case series of 60 infants

Correspondence to Dr Natalie J Smee, Neonatal Unit, NHS Greater Glasgow and Clyde, Glasgow G12 0XH, UK; natalie.smee1@nhs.net We introduced surfactant administration via supraglottic airway (otherwise known as the laryngeal mask airway or LMA) to treat respiratory distress syndrome (RDS) in infants...

Full description

Saved in:
Bibliographic Details
Published inArchives of disease in childhood. Fetal and neonatal edition Vol. 106; no. 3; p. 342
Main Authors Smee, Natalie J, Boyd, Duncan, Conetta, Hilary, O'Shea, Joyce
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 01.05.2021
Subjects
Airway management
Carbon dioxide
Catheters
Infants
Intubation
Pneumothorax
Respiratory distress syndrome
Success
Surfactants
United Kingdom > UK
neonatology
therapeutics
Online AccessGet full text

Cover

More Information
Summary:Correspondence to Dr Natalie J Smee, Neonatal Unit, NHS Greater Glasgow and Clyde, Glasgow G12 0XH, UK; natalie.smee1@nhs.net We introduced surfactant administration via supraglottic airway (otherwise known as the laryngeal mask airway or LMA) to treat respiratory distress syndrome (RDS) in infants greater than 1.2 kg in two Scottish neonatal units (level 3 and level 2). An LMA (i-gel) was then inserted and placement confirmed by colormetric carbon dioxide detector. LMAs are not yet available for most tiny infants but for infants greater than approximately 1.5 kg we feel that LMA surfactant shows great promise, especially in non-tertiary neonatal units.4 Twitter @smee_natalie, @oshea_jem Contributors NJS and JOS wrote the first draft of the manuscript.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:1359-2998
1468-2052
DOI:10.1136/archdischild-2020-320438